Market Cap
$3.6B
XENE
Xenon Pharmaceuticals Inc.
$38.02 ▼ -2.34%
Prev close $38.93Market cap$3.6B
ConsensusStrong Buy
12-mo target$74.31 (+95.5%)
▲ Bullish
Analyst conviction 10/10
Insider Buying Cluster (2 insiders)32 New Institutional Positions18 Institutional Exits Biotech & Drug Discovery
Snapshot
The big-picture read on XENE right now — valuation, ownership and activity at a glance.
Cap Size
Mid Cap
Analyst Consensus
Strong Buy (96%)
Inst. Holders
50 funds
Inst. Value
$4.4B
Inst. Activity
32 buys / 18 sells
Insider Activity
$1.7M buy / $14.6M sell
Insider Net $
-$12.9M
SEC Reports
8
Press Releases
3
Price chart 30d -37.1%
Daily candles (open–high–low–close) with volume. Green = up day, red = down day.
No data for this timeframe.
Vol
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 2, 2026 other
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
VANCOUVER, BC and BOSTON, MA, Oct. 02, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:
Sep 30, 2026 Insider
MORTIMER IAN bought 30,000 shares
PRESIDENT & CEO @ $37.38 ($1.1M)
Sep 30, 2026 Insider
Kelly Thomas Patrick bought 15,000 shares
Chief Financial Officer @ $37.32 ($559.7K)
Sep 1, 2026 Insider
Jul 2, 2026 Press Svoronos Dawn acquired via exercise 5,144 shares
Director @ $8.15 ($41.9K)
Xenon Pharmaceuticals granted 20,200 stock options and 11,850 RSUs to four new non-officer employees as inducement equit
Impact 1/10
Jun 30, 2026 Inst.
BlackRock, Inc. — ADD
7,522,482 shares ($454.1M)
Jun 30, 2026 Inst.
Jun 5, 2026 SEC JPMORGAN CHASE & CO — ADD
2,617,360 shares ($157.4M)
Director Gary Patou filed a Form 144 notice of intent to sell 1,322 shares of Xenon Pharmaceuticals common stock, valued
144 — Impact 2/10
Analyst ratings buy % +0.0%
How Wall Street rates the stock today, and the latest firm-by-firm actions.
96% rate it Buy or better · 26 analysts
Recent analyst actions
| Date | Firm | Action | Rating | Firm rating |
|---|---|---|---|---|
| Sep 18, 2026 | RBC Capital | MAINTAIN | Outperform | 55% |
| Sep 18, 2026 | Wedbush | MAINTAIN | Outperform | 57% |
| Sep 18, 2026 | Wells Fargo | MAINTAIN | Overweight | 54% |
| Sep 18, 2026 | Deutsche Bank | DOWNGRADE | Hold | 58% |
| Sep 18, 2026 | Needham | MAINTAIN | Buy | 50% |
| Sep 18, 2026 | Baird | MAINTAIN | Outperform | 54% |
| Aug 7, 2026 | RBC Capital | MAINTAIN | Outperform | 55% |
| May 27, 2026 | JP Morgan | MAINTAIN | Overweight | 55% |
| May 12, 2026 | JP Morgan | MAINTAIN | Overweight | 55% |
| May 8, 2026 | RBC Capital | MAINTAIN | Outperform | 55% |
Monthly consensus history
| Period | Str. Buy | Buy | Hold | Sell | Str. Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Sep 1, 2026 | 11 | 14 | 1 | 0 | 0 | 96% | |
| Aug 1, 2026 | 11 | 14 | 1 | 0 | 0 | 96% | |
| Jul 1, 2026 | 11 | 14 | 1 | 0 | 0 | 96% | |
| Jun 1, 2026 | 11 | 14 | 1 | 0 | 0 | 96% | |
| May 1, 2026 | 11 | 14 | 1 | 0 | 0 | 96% | |
| Apr 1, 2026 | 11 | 14 | 1 | 0 | 0 | 96% | |
| Mar 1, 2026 | 11 | 15 | 1 | 0 | 0 | 96% | |
| Feb 1, 2026 | 10 | 15 | 1 | 0 | 0 | 96% |
Price targets
Where 18 covering analysts think XENE trades over the next 12 months.
$74.31 +95.5% upside Strong Buy
Current$38.02 Low$46.00 Median$74.50 High$97.00 18 analysts
$46.00$97.00
Analyst rating Strong Buy· 1.3/5 as of Oct 2, 2026
Reports & filings
AI-scored summaries of recent SEC filings and press releases, with sentiment and impact.
8 SEC filing reports analyzed · 0 bullish, 3 bearish, 1 mixed, 4 neutral · avg impact 4.0/10.Plus 3 press releases.
NEUTRAL1442/10
Director Gary Patou filed a Form 144 notice of intent to sell 1,322 shares of Xenon Pharmaceuticals
Jun 5, 2026
NEUTRAL8-K3/10
Xenon Pharmaceuticals filed an 8-K reporting the results of its June 2, 2026 annual meeting, where s
Jun 3, 2026
MIXEDPRESS-RELEASE6/10
Xenon Pharmaceuticals reported Q1 2026 net loss of $102.3M ($1.17/share) vs $65.0M ($0.83/share) in
May 7, 2026
NEUTRALDEFA14A2/10
Xenon Pharmaceuticals filed a definitive proxy statement for its 2025 annual meeting, proposing the
Apr 22, 2026
Upcoming & catalyst events
Scheduled dates plus disclosed catalysts — earnings, dividends, enforcement, FDA and clinical-trial events. Colored dot = impact.
Oct 2, 2026
other
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
VANCOUVER, BC and BOSTON, MA, Oct. 02, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical co
Oct 1, 2026
short_volume
Short Volume: XENE — 55.3% short (0.9M / 1.6M)
Short: 893,302 | Exempt: 376 | TRF Vol: 1,616,288 | Short Ratio: 55.3% | Off-exchange volume (dark pool + OTC)
Sep 22, 2026
short_volume
Short Volume: XENE — 55.2% short (0.5M / 1.0M)
Short: 529,813 | Exempt: 9,350 | TRF Vol: 959,595 | Short Ratio: 55.2% | Off-exchange volume (dark pool + OTC)
Sep 21, 2026
other
Xenon to Present at TD Cowen Novel Mechanisms in Neuropsychiatry & Epilepsy Summit
VANCOUVER, BC and BOSTON, MA, Sept. 21, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical c
Sep 21, 2026
Clinical Trial
A Study to Evaluate the Safety, Tolerability and Efficacy of XEN1101 in Major Depressive Disorder
Phase Phase 2 — COMPLETED
Earnings estimates
Forecast earnings per share and revenue by period — and whether estimates are rising.
| Period | EPS Est. | Range | Growth | 30d Rev | Up/Dn | Revenue | # |
|---|---|---|---|---|---|---|---|
| Current Q | $-1.15 | $-1.29–$-0.94 | -0.0% | +0.7% | 9↑ 4↓ | $0.0B | 13 |
| Next Q | $-1.17 | $-1.35–$-0.85 | 10.7% | +0.8% | 10↑ 3↓ | $0.0B | 13 |
| Current FY | $-4.63 | $-4.93–$-4.06 | -6.2% | +0.1% | 11↑ 2↓ | $0.0B | 14 |
| Next FY | $-4.71 | $-5.50–$-1.90 | -1.9% | +3.1% | 7↑ 5↓ | $0.0B | 14 |
Current-quarter EPS estimate — revision history
| When | EPS estimate | Change vs now |
|---|---|---|
| Current | $-1.150 | — |
| 7d ago | $-1.150 | — |
| 30d ago | $-1.159 | +0.009 |
| 60d ago | $-1.194 | +0.044 |
| 90d ago | $-1.194 | +0.044 |
Institutional ownership
Which big funds own XENE (from quarterly 13F filings) and who is adding or trimming.
50 institutional holders with $4.4B total value (72,252,579 shares) as of 2026-Q2. Top holders: NOMURA, FMR, BlackRock,. Net buying activity: 32 institutions added/increased vs 18 reduced.
Top holders — 2026-Q2
| Fund | Shares | Value | % Tracked | Last move |
|---|---|---|---|---|
| NOMURA ASSET MANAGEMENT CO LTD | 0 | $0.00 | 0.0% | — |
| FMR LLC | 9,647,998 | $582.4M | 13.4% | — |
| BlackRock, Inc. | 7,522,482 | $454.1M | 10.4% | ADD +33.4% |
| Avoro Capital Advisors LLC | 5,777,777 | $348.7M | 8.0% | — |
| Polar Capital Holdings Plc | 4,570,556 | $275.9M | 6.3% | — |
| DRIEHAUS CAPITAL MANAGEMENT LLC | 4,418,557 | $266.7M | 6.1% | — |
| Jupiter Topco LLC | 4,186,519 | $252.7M | 5.8% | — |
| JPMORGAN CHASE & CO | 2,617,360 | $157.4M | 3.6% | ADD +36.1% |
| Capital International Investors | 2,361,639 | $142.5M | 3.3% | — |
| STATE STREET CORP | 1,969,629 | $118.9M | 2.7% | — |
Recent position changes
| Fund | Action | Prev | Current | Change | Value |
|---|---|---|---|---|---|
| BlackRock, Inc. | ADD | 5,640,118 | 7,522,482 | +33.4% | $454.1M |
| JPMORGAN CHASE & CO | ADD | 1,923,610 | 2,617,360 | +36.1% | $157.4M |
| WELLINGTON MANAGEMENT GROUP LLP | TRIM | 4,829,641 | 1,425,492 | -70.5% | $86.0M |
| CITADEL ADVISORS LLC | TRIM | 2,652,990 | 1,401,242 | -47.2% | $84.6M |
| GEODE CAPITAL MANAGEMENT, LLC | ADD | 1,092,932 | 1,370,114 | +25.4% | $82.7M |
| Pictet Asset Management Holding SA | ADD | 679,709 | 1,187,723 | +74.7% | $71.6M |
| Nuveen, LLC | DOUBLED | 250,036 | 993,126 | +297.2% | $59.9M |
| AMERICAN CENTURY COMPANIES INC | ADD | 679,314 | 884,319 | +30.2% | $53.4M |
| VANGUARD PORTFOLIO MANAGEMENT LLC | ADD | 543,062 | 749,651 | +38.0% | $45.2M |
| Alyeska Investment Group, L.P. | TRIM | 1,299,469 | 697,692 | -46.3% | $42.1M |
Insider activity
Buying and selling by company executives and directors (SEC Form 4).
11 insiders, 50 transactions. Net -$12.9M — $1.7M bought, $14.6M sold.
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Sep 30, 2026 | MORTIMER IAN | PRESIDENT & CEO | BUY | 30,000 | $37.38 | $1.1M |
| Sep 30, 2026 | Kelly Thomas Patrick | Chief Financial Officer | BUY | 15,000 | $37.32 | $559.7K |
| Sep 1, 2026 | Svoronos Dawn | Director | EXERCISE | 5,144 | $8.15 | $41.9K |
| Aug 28, 2026 | KENNEY CHRISTOPHER JOHN | Chief Medical Officer | SELL | 6,368 | $60.17 | $383.1K |
| Aug 28, 2026 | KENNEY CHRISTOPHER JOHN | Chief Medical Officer | SELL | 700 | $60.98 | $42.7K |
| Aug 11, 2026 | GANNON STEVEN | Director | SELL | 10,000 | $64.06 | $640.6K |
| Jun 5, 2026 | Cannon Gillian | Director | SELL | 1,190 | $53.14 | $63.2K |
| Jun 5, 2026 | PATOU GARY | Director | SELL | 1,322 | $53.14 | $70.3K |
| Jun 3, 2026 | Gover Justin D. | Director | AWARD | 10,507 | — | — |
| Jun 3, 2026 | Machado Patrick | Director | AWARD | 10,507 | — | — |
Short interest & halts
FINRA semi-monthly short positions, Reg SHO threshold status, and recent trading halts for XENE.
Shares short
6,444,815
Settlement Sep 15, 2026
Change vs prior
+1.6%
Semi-monthly cycle
Days to cover
12.2
At avg daily volume
Of shares outstanding
≈6.7%
Estimate — not % of float
All XENE filing & press-release reports (11)
- PRESS-RELEASE reportJul 2, 2026
- 144 reportJun 5, 2026
- 8-K reportJun 3, 2026
- PRESS-RELEASE reportMay 7, 2026
- DEFA14A reportApr 22, 2026
- PRESS-RELEASE reportApr 19, 2026
- PRESS-RELEASE reportApr 15, 2026
- 8-K reportApr 13, 2026
- PRESS-RELEASE reportApr 7, 2026
- CLUSTER reportMar 14, 2026
- PRESS-RELEASE reportMar 12, 2026